Egypt to start local production of Sinovac covid-19 vaccine as of June 2021
#Covid19 #Health #Vaccine #EGYPT
Agence Ecofin
Tuesday 11 May 2021 Last update on Tuesday, May 11, 2021 At 12:55 PM

The country of the pharaohs had already obtained in April, an agreement with Russia to produce the Sputnik V vaccine through a technology transfer program. The country hopes to meet the needs of its covid-19 vaccination campaign immediately.

Egypt will begin local production of the Sinovac vaccine against covid-19, as of June 2021. This was announced by Egyptian Minister of Health, Hala Zayed, during a press conference Sunday May 9.

According to the official, the manufacturing process will be handed over to the Egyptian Company for Biologics and Vaccines (VACSERA) with the delivery of a “first shipment of raw materials needed to manufacture the vaccine on May 18”. During the month of June, 2 million doses of the vaccine called Sinovac-Vacsera will be produced by the laboratory. A total of 40 million doses are planned for the first year of manufacture.

The production of vaccines in the land of the Pharaohs is governed by two agreements signed between VACSERA and the biopharmaceutical company Sinovac on April 21, 2021. The first provides Egypt with technical assistance and expertise from Sinovac and the second grants the laboratory Egyptian license for the manufacture, repackaging and packaging of the vaccine produced.

As a reminder, Egypt had already received Russian approval for the local production of 40 million doses of the Sputnik V vaccine per year.

This new approach comes as the Egyptian government has stepped up the measures taken as part of the continuation of the vaccination campaign launched since January. Indeed, during her speech, Hala Zayed indicated that the country would continue to receive vaccines, in particular thanks to the Covax initiative and the Sinopharm laboratory.

Note that the Sinovac-Vacsera vaccines produced will undergo an evaluation for a few weeks by the Egyptian Medicines Authority (EDA) before being distributed.

React to this article

Your comments

Rejoignez la discussion

Your email address will not be published. Required fields are marked *